Literature DB >> 33093123

Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.

Yong-Soo Kwon1, Doosoo Jeon2, Hyungseok Kang3, Jae-Joon Yim4, Tae Sun Shim5.   

Abstract

Entities:  

Year:  2021        PMID: 33093123     DOI: 10.1183/13993003.03026-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  2 in total

1.  Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Hossein Hatami; Giovanni Sotgiu; Narjess Bostanghadiri; Sahel Shafiee Dolat Abadi; Bita Mesgarpour; Hossein Goudarzi; Giovanni Battista Migliori; Mohammad Javad Nasiri
Journal:  J Bras Pneumol       Date:  2022-05-30       Impact factor: 2.800

2.  Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.

Authors:  Helena Huerga; Uzma Khan; Mathieu Bastard; Carole D Mitnick; Nathalie Lachenal; Palwasha Y Khan; Kwonjune J Seung; Nara Melikyan; Saman Ahmed; Michael L Rich; Francis Varaine; Elna Osso; Makhmujan Rashitov; Naseem Salahuddin; Gocha Salia; Epifanio Sánchez; Armine Serobyan; Muhammad Rafi Siddiqui; Dri Grium Tefera; Dmitry Vetushko; Lusine Yeghiazaryan; David Holtzman; Shirajul Islam; Andargachew Kumsa; Gamarly Jacques Leblanc; Olga Leonovich; Shahid Mamsa; Mohammad Manzur-Ul-Alam; Zaw Myint; Shrivani Padayachee; Molly F Franke; Catherine Hewison
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.